ARTICLE | Clinical News
AlloStim: Phase I/II data
June 11, 2012 7:00 AM UTC
Immunovative Therapies Ltd., Shoham, Israel Product: AlloStim Business: Cancer Molecular target: NA Description: IV formulation of activated CD4+ T cells Indication: Treat refractory solid tumors End...